CAL Investors Have Opportunity to Join Caleres, Inc. Fraud Investigation with the Schall Law Firm

LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Caleres, Inc. ('Caleres' or 'the Company') (NYSE: CAL) for violations of the securities laws.
The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Caleres reported its financial results for Q1 2025 on May 29, 2025. The Company reported sales of $614.2 million, a 6.8% year-over-year decline. The Company acknowledged its sales were 'below our expectations.' The Company also suspended its guidance for 2025 due to 'uncertainty in the environment.' Based on this news, shares of Caleres fell by more than 18.2% on the same day.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at bschall@schallfirm.com.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Upturn

38 minutes ago

• Business Upturn

NurExone Advances U.S. Growth Strategy with Acceptance into Prestigious ARMI HealthTech Hub Accelerator and Provides Corporate Update

By GlobeNewswire Published on June 20, 2025, 11:30 IST TORONTO and HAIFA, Israel, June 20, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) ('NurExone' or the 'Company'), a biotech company developing exosome-based therapies for central nervous system injuries, announced today that it has been accepted into the HealthTech Hub ('HTH') Accelerator Program. Based in Boston, Massachusetts, home to more than 1,000 biotech companies1, HTH is operated by the Advanced Regenerative Manufacturing Institute ('ARMI') and its BioFabUSA initiative. NurExone's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market following the establishment of Exo-top Inc. ('Exo-TOP'), the Company's wholly owned U.S. subsidiary dedicated to GMP-compliant exosome manufacturing for clinical development and commercial scale-up. HTH, co-led by ARMI and Mass General Brigham, is a competitive accelerator program supported by the U.S. Department of Health and Human Services and Israel's Ministry of Health. The HTH Accelerator Program selects a limited number of innovative companies each year to help them validate U.S. clinical relevance, strengthen commercialization strategies, and build meaningful collaborations with key stakeholders across the U.S. HealthTech landscape. The program is funded by HTH at no cost to participants. Dr. Lior Shaltiel, CEO of NurExone, commented: 'The HTH Acceleration Program offers the kind of U.S.-based insight and guidance needed at this stage of our growth. As we establish Exo-TOP to manufacture clinical-grade exosomes in the U.S., the HTH will help us sharpen our regulatory and scale-up strategies and pursue meaningful commercial collaboration opportunities. This is a timely and strategic opportunity to accelerate our commercialization pathway in the world's largest healthcare market 2 .' NurExone's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and to support its mission to bring novel exosome-based therapeutics to patients with unmet needs. Omnibus Plan Approval The Company is pleased to announce that, further to its press release dated June 4, 2025, at the Company's annual general and special meeting held on June 18, 2025 (the 'Meeting'), disinterested shareholders ratified and approved the amended and restated omnibus incentive plan (the 'Omnibus Plan'), a copy of which is available under the Company's SEDAR+ profile at The Omnibus Plan is a hybrid plan that provides flexibility to grant-equity incentive awards in the form of stock options ('Options'), restricted shares ('Restricted Shares') and restricted share units ('RSUs'). The Omnibus Plan is a hybrid 10% rolling and 10% fixed share-based compensation plan that amends and restates the Company's previous equity incentive plan approved by shareholders on June 4, 2024 (the 'Previous Plan'). The Previous Plan was a 20% fixed share-based compensation plan whereby the maximum number of common shares in the capital of the Company ('Common Shares') reserved for issuance was set at 13,166,085, representing 20% of the issued and outstanding Common Shares as of the effective date. The Omnibus Plan now includes (i) a 10% 'rolling' Option component that shall not exceed 10% of the Company's total issued and outstanding Common Shares from time to time; and (ii) a 10% fixed component permitting up to 7,800,781 RSUs and Restricted Shares in the aggregate. Additionally, the Omnibus Plan was amended to increase the number of securities issuable to insiders of the Company. The Previous Plan provided, that unless approved by disinterested shareholders, (i) the maximum number of securities issuable to insiders collectively would not exceed 10% of the Company's securities at any time and (ii) the maximum number of securities issuable to insiders collectively in any twelve-month period would not exceed 10% of the Company's total issued and outstanding securities as at the date any award was granted to an insider. Now, the Omnibus Plan provides the following that (i) the maximum number of the Company's securities issuable to insiders collectively shall not exceed 20% of the Company's total issued and outstanding Common Shares at any point in time and (ii) the maximum number of the Company's securities issuable to insiders collectively, in any 12-month period, when combined with all of the Company's other share compensation arrangements, shall not exceed 20% of the Company's total issued and outstanding securities, calculated as at the date any award is granted or issued to any insider. RSU Grants In addition, the Company announced that it has granted an aggregate of 1,125,000 RSUs to certain officers and directors of the Company pursuant to the terms and conditions of the Omnibus Plan. Each RSU vests on the one-year anniversary of the grant date and may be settled, upon their vesting, into one Common Share. The RSUs and underlying Common Shares are subject to the Exchange Hold Period (as such term is defined under the policies of the TSX Venture Exchange ('TSXV')). About NurExone NurExone Biologic Inc. is a TSXV, OTCQB, and Frankfurt-listed biotech company focused on developing regenerative exosome-based therapies for central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury, both multi-billion-dollar marketsi. Regulatory milestones, including obtaining the Orphan Drug Designation, facilitates the roadmap towards clinical trials in the U.S. and Europe. Commercially, the Company is expected to offer solutions to companies interested in quality exosomes and minimally invasive targeted delivery systems for other indications. NurExone has established Exo-Top Inc., a U.S. subsidiary, to anchor its North American activity and growth strategy. For additional information and a brief interview, please watch Who is NurExone?, visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube. For more information, please contact: Dr. Lior ShaltielChief Executive Officer and DirectorPhone: +972-52-4803034 Email: [email protected] Dr. Eva Reuter Investor Relations – GermanyPhone: +49-69-1532-5857 Email: [email protected] Allele Capital Partners Investor Relations – +1 978-857-5075 Email: [email protected] FORWARD-LOOKING STATEMENTS This press release contains certain 'forward-looking statements' that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as 'may', 'will', 'should', 'could', 'expect', 'plan', 'intend', 'anticipate', 'believe', 'estimate', 'predict' or 'potential' or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to: the; the Company's acceptance into the prestigious HTH Accelerator Program will support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program is expected to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof. In developing the forward-looking statements in this press release, we have applied several material assumptions, including: the Company's acceptance into the prestigious HTH Accelerator Program will allow it to support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will give the Company the ability to enhance its visibility within the U.S. regenerative medicine ecosystem and support its mission as discussed herein; each RSU will be settled into one Common Share; and the NurExone platform technology offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications, including recovery of optic nerve function and overall visual health Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to risks related to: the Company's early stage of development; lack of revenues to date; government regulation; market acceptance for its products; rapid technological change; dependence on key personnel; dependence on the Company's strategic partners; the fact that preclinical drug development is uncertain, and the drug product candidates of the Company may never advance to clinical trials; the fact that results of preclinical studies and early-stage clinical trials may not be predictive of the results of later stage clinical trials; the uncertain outcome, cost, and timing of product development activities, preclinical studies and clinical trials of the Company; the uncertain clinical development process, including the risk that clinical trials may not have an effective design or generate positive results; the inability to obtain or maintain regulatory approval of the drug product candidates of the Company; the introduction of competing drugs that are safer, more effective or less expensive than, or otherwise superior to, the drug product candidates of the Company; the initiation, conduct, and completion of preclinical studies and clinical trials may be delayed, adversely affected or impacted by unforeseen issues; the inability to obtain adequate financing; the inability to obtain or maintain intellectual property protection for the drug product candidates of the Company; risks that the Company's intellectual property and technology won't have the intended impact on the Company and/or its business; the Company's inability to carry out its pre-clinical trials and realize upon the stated benefits of the pre-clinical trials; the inability of the Company to realize on the benefits of exosomes; the inability of the Company to produce and/or supply exosomes for a wide range of applications; the inability of the Company's products to be used for patient treatment; there not being broader adoption in the field and/or cell therapy applications; the inability of the Company to fulfill its intended future plans and expectations; there not being growing clinical demand for innovative treatments in spinal cord, optic nerve, and/or other therapeutic areas; the Company's inability to realize upon the stated potential for exosome-loaded drugs in regenerating or repairing damaged nerves; the Company's inability to maintain its ongoing commitment to using its ExoTherapy platform to advance the field of regenerative medicine and/or cell therapy applications; the Company's inability to expand into further studies; the Company will not receive all required regulatory approvals; the Company will not have clinical and/or commercial breakthroughs in regenerative medicine; the Company will be unable to enhance its presence in key markets; the NurExone platform technology not offering novel solutions to drug companies interested in minimally invasive targeted drug delivery for other indications; the Company will not realize its future development plans, operational initiatives, and strategic objectives; the Company will not advance its therapeutic programs and clinical milestones; the Company will not engage with regulatory agencies; the Company's acceptance into the prestigious HTH Accelerator Program will not support the Company's expansion into the U.S. market; the Company's participation in the HTH Accelerator Program will not enhance its visibility within the U.S. regenerative medicine ecosystem and will not support its mission as discussed herein; each RSU will not be settled into one Common Share; and the risks discussed under the heading 'Risk Factors' on pages 44 to 51 of the Company's Annual Information Form dated August 27, 2024, a copy of which is available under the Company's SEDAR+ profile at . These factors should be considered carefully, and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law. Neither TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. i Spinal cord injury, Glaucoma 1 2 Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.

Business Wire

5 hours ago

• Business Wire

Combined Shareholders' Meeting of June 19, 2025: All Submitted Resolutions Were Adopted

NEUILLY-SUR-SEINE, France--(BUSINESS WIRE)--The Combined Shareholders' Meeting of Bureau Veritas (the "Company"), chaired by Mr. Laurent Mignon, Chairman of the Board of directors, was held today at the Company's head office. All resolutions submitted to the Shareholders' Meeting were adopted at a large majority, including: The approval of the statutory and consolidated financial statements for the financial year ending on December 31, 2024, and the approval of a dividend distribution of €0.90 per share to be paid in cash on July 3, 2025 (ex-date on July 1, 2025) on positions closed on July 2, 2025; The approval of a related-party agreement concerning the Company's participation in Wendel's share placement (acquisition by the Company of its own shares); The approval of the report on Corporate Officers' compensation; The approval of fixed, variable and extraordinary components of the total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mr. Laurent Mignon, in his capacity as Chairman of the Board of Directors; The approval of fixed, variable and extraordinary components of total compensation and benefits-in-kind paid or awarded for the 2024 financial year to Mrs. Hinda Gharbi, in her capacity as Chief Executive Officer; The approval of the compensation policy for the Directors, the Chairman of the Board of Directors and the Chief Executive Officer for 2025; The authorization granted to the Board of Directors to trade in the Company's ordinary shares; The delegations and/or financial authorizations granted to the Board of Directors. The Shareholders' Meeting renewed the term of office as Director of Mr. Laurent Mignon, and the Board of Directors reappointed him as Chairman of the Board of Directors. The Shareholders' Meeting also renewed the terms of office as Directors of Ms. Julie Avrane, Ms. Ana Giros Calpe and Mr. Jérôme Michiels. Ms. Lucia Sinapi-Thomas is leaving the Board, as her term of office has expired. The Directors commended her contribution to the Board's discussions and decisions, as well as to the work of its Committees. To replace Ms. Sinapi-Thomas, the Shareholders' Meeting appointed Ms. Elodie Perthuisot as an independent director for a term of four years. Elodie Perthuisot is a member of the Carrefour Group's Executive Committee and currently heads Carrefour Spain, one of the group's main subsidiaries. Holding an engineering degree from the École Polytechnique, she began her career in the public sector - she notably headed the office of Frédéric Mitterrand, Minister of Culture and Communication - before joining the retail sector, leading the commercial management and multichannel transformation of Fnac and then Fnac Darty. She joined Carrefour in 2018 where she has successively led the marketing in France, e-commerce and, since 2021, the group's digital and technological transformation. Under her leadership, Carrefour has significantly accelerated its digital and data ambitions, becoming a company recognized for its progress in these areas. The Bureau Veritas Board of Directors will be able to rely on her diverse experience, and in particular on her expertise in digital transformation and operational management. In the activity reports, Mrs. Hinda Gharbi, Chief Executive Officer, and Mr. François Chabas, Chief Financial Officer, presented the 2024 highlights, the 2024 financial results, providing specific details on revenue, adjusted operating profit, net earnings per share, cash flow statement and the financial position. Mrs. Hinda Gharbi, Chief Executive Officer, then presented the review of the Group's activities for the 2024 financial year, and detailed the first quarter revenue as well as the 2025 outlook. She also provided an update on the LEAP I 2028 strategic plan. Mr. Laurent Mignon and Mr. Pascal Lebard, Lead Independent Director, respectively presented corporate governance and compensation components of the Directors, the Chairman of the Board of directors and the Chief Executive Officer in 2024, as well as the compensation policies. The broadcast of the Shareholders' Meeting, including the full presentation and the complete results of the vote of the resolutions, will be available on the Company's website ( ABOUT BUREAU VERITAS Bureau Veritas is a world leader in inspection, certification, and laboratory testing services with a powerful purpose: to shape a world of trust by ensuring responsible progress. With a vision to be the preferred partner for customers' excellence and sustainability, the company innovates to help them navigate change. Created in 1828, Bureau Veritas' 84,000 employees deliver services in 140 countries. The company's technical experts support customers to address challenges in quality, health and safety, environmental protection, and sustainability. Bureau Veritas is listed on Euronext Paris and belongs to the CAC 40, CAC 40 ESG, SBF 120 indices and is part of the CAC SBT 1.5° index. Compartment A, ISIN code FR 0006174348, stock symbol: BVI. For more information, visit and follow us on LinkedIn. Our information is certified with blockchain technology. Check that this press release is genuine at

Business Insider

6 hours ago

• Business Insider

Nio or XPeng: Goldman Sachs Chooses the Superior EV Stock to Buy

Since 2009, China has held the title of the world's largest automotive market, driven by its vast population and a rapidly growing urban middle class. In 2022 alone, the country recorded 26.88 million new car sales. By the following year, domestic production surged past 31 million vehicles. So far this year, Chinese auto sales have made up 28% of the global total. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter A key driver of this growth is the rapid adoption of electric vehicles (EVs), which are claiming an ever-larger share of the market. Backed by robust government support and rising consumer demand, EV production and adoption have soared. China is now home to around 100 active EV makers, and its EV market is the largest in the world. According to Fortune Business Insights, the electric car market in China is expected to grow at a strong CAGR of approximately 18.4% through 2030. But with this rapid expansion comes intensifying competition. The EV boom has turned the market into a fierce battleground, where price wars and shrinking margins are becoming the norm. For investors, the rapid expansion of China's EV sector brings both opportunities and pitfalls. Goldman Sachs analyst Tina Hou is closely following the action, focusing on two of China's most prominent EV names: Nio (NYSE:NIO) and XPeng (NYSE:XPEV). Her insights aim to separate the leader from the laggard, and help investors determine which stock offers the more compelling case. Let's take a closer look. Nio We'll start with Nio, one of China's innovative electric car makers. Since its founding in 2014, Nio has developed a line-up of EV models, nine under its own nameplate along with additional models under the Onvo and Firefly brands. The company's vehicle lines include several sedan and SUV models, combining luxury styling, the latest EV tech, digital dashboards, and long-range battery systems. On pricing, Nio aims to run the gamut – from low-end budget models to high-priced luxury offerings. At bottom, the company's Onvo and Firefly brands feature ticket prices as low as $16,700 for Firefly's low-cost trim, to $33,400 for the top-end Onvo model. Nio's eponymous nameplate features vehicles such as the ET5, at $41,000, the ET7, priced at $59,000, and the ET9 for $90,000. Vehicle pricing is based on battery technology and packages, vehicle trim levels, and idiosyncrasies of local region and market conditions. Nio backs up its vehicles with a solid service network. The company pioneered EV battery swapping in China, developing a network of swapping stations where vehicle owners and drivers can pull in and replace depleted battery packages for new ones – without having to wait for recharging. The service is offered on a subscription basis, and has proven popular with Nio's customer base, as it solves two 'pains' that EV drivers frequently complain of: long battery charging times and high battery costs. We should note here that Nio has faced headwinds in recent months. The company's stock is down 22% year-to-date, after the firm has faced difficulties hitting sales goals and has cut delivery guidance. The lowered guidance has come alongside lower delivery numbers and increased quarterly earnings losses. On the delivery side, Nio delivered 23,900 vehicles in April of this year, for a 53% year-over-year gain; in May, that number was 23,231 vehicles, for a year-over-year gain of 13.1%. On revenue and earnings, Nio reported $1.66 billion in 1Q25, up 21.5% year-over-year but missing the forecast by $70 million. At the bottom line, Nio's non-GAAP EPS loss in Q1, of 41 cents, was 4 cents per share below the forecast; the company's net loss was 24% deeper than in the prior-year quarter. In her write-up on Nio for Goldman, analyst Tina Hou notes that company management is actively working to improve efficiencies and mitigate losses, but has not reaped the benefits yet. 'Nio has been focusing on cost reduction through a series of cost control and efficiency improvement measures since Mar, including terminating low return projects, and integrating R&D and S&M teams to support multiple brands with a c.20% headcount reduction. By doing so, management aims to achieve 20%-25% opex optimization and profit breakeven in 4Q25… Although we believe Nio's cost reduction efforts would help improve the company's R&D and operational efficiency, we remain relatively more conservative on Nio's FY25 sales volume compared to management's target largely due to the ongoing industry competitive intensity, YTD run rate and overall demand outlook,' Hou stated. Hou follows these comments with a Neutral (i.e., Hold) rating on NIO, along with a $3.80 price target that points toward a one-year upside of 11%. (To watch Hou's track record, click here) This view is in line with the Street's consensus; Nio has a Hold rating, based on 11 recent reviews which include 2 to Buy, 8 to Hold, and 1 to Sell. The shares are priced at $3.42, and their $4.51 average price target suggests a ~32% gain in the next 12 months. (See NIO stock forecast) XPeng, Inc. Next on our list here is XPeng, a fast-growing EV maker in the Chinese market. The company is based in the southern city of Guangzhou, where it was founded in 2014. XPeng started regular vehicle production in 2019, and in recent months has seen its production and delivery numbers grow rapidly. XPeng's current success is based on a line-up of battery-powered EVs that include elegant luxury models, large SUVs, a coupe, and even an extra-large seven-seater. Customers can choose from a range of features, including luxury-styled interior finishing, long-range battery packs, flat-screen cockpits, and voice-activated driving assistance. XPeng's vehicles are aimed at China's growing upper-middle-class demographic, a population that has the available funds to buy high-end electric vehicles and is tech-savvy enough to appreciate and use the added smart-car technology features. While the company has put a premium on high-tech features in its cars, it hasn't skimped on basic automotive technology; XPeng's cars are powered by proven electric drivetrains to provide drivers with a favorable driving experience. To support its vehicles and customers, XPeng provides solid warranties for its vehicles and their systems, along with remote vehicle support and diagnostics, and 24/7 roadside assistance. On a more prosaic level, the company has also built up a network of 772 branded supercharging stations and 1,870 free charging stations. The network spans China, and includes 319 cities with free charging services. The company's supercharging technology includes built-in safety monitoring, to ensure that fast chargers are safe to use. In its last reported quarter, 1Q25, XPeng reported quarterly deliveries of 94,008 vehicles, covering all models. This number was up 331% year-over-year, and reflects increasing sales success in the past year. The company's most recent delivery numbers, covering this past May, came in at 33,525 total vehicles – a figure that was up 230% year-over-year. XPeng has recorded monthly vehicle deliveries of 30,000-plus for seven consecutive months. Looking at financial results, we find that XPeng generated $2.18 billion in revenues, in line with expectations and achieving a year-over-year gain of 141.5%. At the bottom line, XPeng recorded a net loss of 6 cents per share by non-GAAP measures – but that net loss was significantly less than had been expected, beating the forecast by 15 cents per share. Recognizing the momentum, Goldman Sachs analyst Tina Hou sees particular strength in XPeng's ability to scale up new model launches and maintain a steady pace of innovation. 'Since 4Q24, XPeng has shown consistent improvement in its new and refreshed model launches with Mona M03 and P7+ sales volume ranking among the top 3 in their respective segment. XPeng has also stepped up on its new model launch frequency with 10 over 2024-2026, compared to only 1-2 new models each year from 2019-2023. XPeng will now introduce 10 new + refresh models each year to better compete in today's highly dynamic market environment… We are Buy-rated, as we see the result of a series of efforts coming through that has transformed the company's product and cost structure competitiveness, leading to higher visibility for sustainable sales volume growth as well as profit margin improvement going forward. XPeng is currently trading in line with historical average forward P/S multiple in the past 1 year,' the analyst opined. That stated Buy rating is complemented by a price target of $24, suggesting a 29% potential upside for the next 12 months. The Street, generally, likes XPEV shares, and gives the stock a Moderate Buy consensus rating based on 9 recent reviews with a breakdown of 6 Buys, 2 Holds, and 1 Sell. The stock's $18.61 selling price and $24.78 average target price together indicate room for a 33% gain in the coming year. (See XPEV stock forecast) With the facts laid out, and the ratings and price targets compared side-to-side, it's clear that Goldman Sachs has picked out XPeng as the superior Chinese EV stock to buy. To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.